Next-Generation Bispecific Nanobody Targeting FCGR3A and FAP for the Treatment of Autoimmune Disease

VHH-P222 is a highly innovative, fully human bispecific nanobody developed to target both Fc gamma receptor IIIa (FCGR3A) and fibroblast activation protein alpha (FAP). Designed as a dual-action therapeutic, VHH-P222 is currently undergoing biological testing and demonstrates strong potential for application in autoimmune disease therapy. By addressing both key immunological and stromal components implicated in autoimmune conditions, this antibody drug candidate aims to deliver improved specificity and efficacy compared to conventional therapies. The strategic focus on FCGR3A and FAP as therapeutic targets underlines the potential of VHH-P222 as a unique treatment option within the landscape of autoimmune disease management.

Licensing Opportunity

VHH-P222 is currently open for out-licensing and strategic partnerships. We invite collaborations with biopharmaceutical companies interested in advancing innovative bispecific nanobody therapeutics for autoimmune disease.

Development Phase

Modality

VHH-P222 is constructed as a bispecific antibody fusion consisting of an anti-human CD16A single-domain (nanobody) antibody joined to a human IgG1 Fc region and further linked to an anti-human FAP single-chain variable fragment via a flexible (G4S)3 linker, and is expressed in HEK293 cells. As a nanobody, its single-domain architecture confers superior tissue penetration and heightened stability compared to conventional monoclonal antibodies. The small molecular size enables better access to tissue compartments commonly involved in autoimmune diseases, while the IgG1 Fc fusion promotes desirable effector functions. This modular design allows for simultaneous engagement of immune effector cells and stromal elements, representing a promising modality for sophisticated immune modulation.

Target

FCGR3A and FAP are two critical molecular targets in immune and stromal biology. FCGR3A, an activating receptor predominantly found on natural killer (NK) cells and subsets of macrophages, plays a pivotal role in antibody-dependent cellular cytotoxicity and immune regulation. FAP is a cell surface serine protease overexpressed in activated fibroblasts present in pathological tissues, including areas of chronic inflammation and tissue remodeling typical in autoimmune disease. The joint targeting of FCGR3A and FAP enables precise modulation of both immune cell function and the fibrotic microenvironment. This strategic approach holds promise for attenuating aberrant immune responses while addressing pathological stroma, underscoring the commercial and scientific relevance of VHH-P222 in treating autoimmune disorders.

Mechanism of Action

VHH-P222 is engineered to bind specifically to FCGR3A on immune effector cells and FAP on activated fibroblasts. By engaging both targets, it modulates immunological signaling pathways and stromal cell activity. This dual binding facilitates the recruitment of cytotoxic immune responses directly to pathogenic fibroblast-rich sites, potentially suppressing inflammatory and fibrotic pathways associated with autoimmune disease progression. The nanobody-based fusion platform supports the possibility of future extension into ADCs and other multi-functional antibody therapeutics, providing a flexible foundation for innovative, next-generation immune-modulating therapies beyond traditional approaches.

Autoimmune Disease

Autoimmune diseases comprise a broad category of chronic disorders characterized by an aberrant immune response directed against self-antigens, leading to tissue inflammation and damage. These conditions encompass diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, among others. Globally, autoimmune diseases collectively affect millions, creating significant health and socioeconomic burdens. Current therapies typically include immunosuppressive agents, biologics targeting specific cytokines, and symptomatic treatments. However, these approaches are often limited by incomplete efficacy, risk of opportunistic infections, and off-target side effects. Unmet medical needs remain high, particularly the demand for therapies that selectively modulate pathological immune pathways without broadly impairing host defenses. VHH-P222, by simultaneously targeting FCGR3A and FAP, offers the prospect for more streamlined and tissue-focused immune modulation, potentially overcoming current treatment limitations and delivering superior disease control in autoimmune settings.